Why the study?
Does treatment with Rycal S107 or LVAD alter Ryanodine receptor calcium leak in circulating B-lymphocytes in mice and patients with CHF?
Does treatment with Rycal S107 or LVAD alter Ryanodine receptor calcium leak in circulating B-lymphocytes in mice and patients with CHF?
Ryanodine receptor calcium leak in circulating B-lymphocytes may serve as a novel biomarker for monitoring response to pharmacological and mechanical CHF therapy.
Answers are grounded in this paper and cite their sources.
May support B-lymphocyte calcium leak as a CHF therapy biomarker; leaves open validation before clinical adoption.
BACKGROUND: handling because of leaky RyR channels in CHF. METHODS: stores within the endoplasmic reticulum. RESULTS: leak was significantly reduced in mice treated with the Rycal S107. Patients with CHF treated with left-ventricular assist devices exhibited a heterogeneous response. CONCLUSIONS: handling and systemic sympathetic burden, presenting a novel biomarker for monitoring response to pharmacological and mechanical CHF therapy.
No takes yet. Share an insight, caveat, or question.
Kushnir et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: